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Interleukin-2 (IL-2) is a cytokine required for effector T cell expansion, survival, and function, especially for engineered T cells in adoptive cell immunotherapy, but its pleiotropy leads to simultaneous stimulation and suppression of immune responses as well as systemic toxicity, limiting its therapeutic use. We engineered IL-2 cytokine-receptor orthogonal (ortho) pairs that interact with one another, transmitting native IL-2 signals, but do not interact with their natural cytokine and receptor counterparts. Introduction of orthoIL-2Rb into T cells enabled the selective cellular targeting of orthoIL-2 to engineered CD4 + and CD8 + T cells in vitro and in vivo, with limited off-target effects and negligible toxicity. OrthoIL-2 pairs were efficacious in a preclinical mouse cancer model of adoptive cell therapy and may therefore represent a synthetic approach to achieving selective potentiation of engineered cells.
A doptive transfer of tumor-reactive T cells has evolved into a clinically useful therapy capable of inducing antitumor immunity in patients (1, 2) . However, the broad application of adoptive T cell transfer (ACT) therapies to treat cancer has several limitations, including the production of sufficient quantities of cells for infusion and the failure of transferred T cells to persist and remain functional in vivo. In the clinic, the concomitant administration of the T cell growth factor interleukin-2 (IL-2) improves the survival, function, and antitumor activity of transplanted T cells (3, 4) . However, the use of IL-2 to potentiate ACT is complicated by the pleiotropic nature of IL-2, which induces both immune stimulatory and suppressive T cell responses as well as potentially severe toxicities (5) . This is governed by the interaction between IL-2 and the IL-2 receptor (IL-2R), which consists of a, b, and g subunits (6) . IL-2Rb and the common g-chain (IL-2Rg) together form the signaling dimer and bind IL-2 with moderate affinity, whereas IL-2Ra (CD25) does not signal but increases the affinity of IL-2 for the binary (bg) IL-2 receptor to sensitize T cells to low concentrations of IL-2.
The activity of IL-2 as an adjuvant to ACT is dependent on the balance between activation of transplanted and endogenous T cell subsets bearing natural IL-2 receptors, as well as host responses that cause dose-limiting toxicities. Strategies to overcome these limitations could improve T cell immunotherapy (7, 8) . Recognizing the need for new approaches that afford precise targeting of IL-2-dependent functions to a specific cell type of interest, we devised a strategy to redirect the specificity of IL-2 toward adoptively transferred T cells. This method, based on receptor-ligand orthogonalization, uses a mutant IL-2 cytokine and mutant IL-2 receptor that bind specifically to one another but not to their wild-type counterparts (Fig. 1A) .
We focused on the murine IL-2/IL-2Rb interaction to enable in vivo characterization in syngeneic mouse models. The IL-2Rb chain was chosen as the mutant receptor because the b chain is required for signal transduction and can bind IL-2 independently. We devised a twostep approach to engineer orthogonal IL-2/IL2Rb pairs informed by the crystal structure of the IL-2 high-affinity receptor complex (6) (Fig. 1B) . First, point mutations of the IL-2Rb chain were identified from inspection of the interface between IL-2 and IL-2Rb that abrogated binding to wild-type IL-2 ( Fig. 1, C to E) . The IL-2Rb hotspot residues His 134 and Tyr 135 make numerous contacts with IL-2 that contribute a majority of the binding free energy between IL-2 and IL-2Rb (6) (Fig. 1E) Fig. 1D) , even in the presence of CD25 ( fig. S1) (7, 9) .
Next, we used yeast display-based evolution to mutate, and thus remodel, the wild-type IL-2 interface region that was opposing (or facing the site of) the IL-2Rb mutations in the crystal structure, in order to create a molecule that bound to orthoIL-2Rb but not to wild-type IL-2Rb. IL-2 residues in proximity to the orthoIL-2Rb binding interface were randomly mutated and were chosen on the basis of a homology model of the mouse IL-2/IL-2Rb complex (Fig. 1E ) derived from the crystal structure of the human IL-2 receptor complex (6) . A library of~10 8 unique IL-2 mutants was displayed on the surface of yeast ( fig. S2 ) and subjected to multiple rounds of both positive (against orthoIL-2Rb) and negative (against IL2Rb) selection (figs. S2 and S3). This collection of yeast-displayed IL-2 mutants bound the orthoIL2Rb, but not wild-type IL-2Rb, and retained CD25 binding (Fig. 1D) . Sequencing of yeast clones from the evolved IL-2 libraries revealed a consensus set of mutations at IL-2 positions in close structural proximity to the orthoIL-2Rb mutations ( fig. S4 ). Interestingly, a Gln 30 → Asn (Q30N) mutation was highly conserved across three independent mutant IL-2 yeast libraries, whereas all other IL-2 positions used a restricted but not specific mutational signature. We found that IL-2 mutations Q30N, Met 33 → Val (M33V), and Asp 34 → Leu or Met (D34L/M) appear to form a small nonpolar pocket to compensate for the IL-2Rb Y135F mutation, whereas Gln 36 → Thr, Ser, Lys, or Glu (Q36T/S/K/E) and Glu 37 → Tyr or His (E37Y/H) mutations present a polar or charged surface to compensate for the IL-2Rb H134D mutation (Fig. 1F) .
Because of the affinity-enhancing effects of CD25 expression on the interaction of IL-2 with the binary (bg) IL-2 receptor (10), IL-2 mutants with negligible binding to IL-2Rb alone may still form a functional signaling complex on cells that also express CD25 (8) . Therefore, we used a yeastbased functional screen to further triage IL-2 mutants that bound specifically to the orthoIL-2Rb and signaled selectively on T cells that express the orthoIL-2Rb (Fig. 1G and fig. S5 ), and produced recombinant forms of select IL-2 mutants (orthoIL-2) for characterization (figs. S6 to S8).
We focused our efforts on two orthoIL-2 mutants, 1G12 and 3A10. OrthoIL-2 1G12 and 3A10 share the consensus Q30N, M33V, and D34L mutations but differ at positions Glu (Fig. 1I ). OrthoIL-2 1G12 and 3A10 bound the orthoIL-2Rb with an affinity comparable to that of the wild-type IL-2/IL-2Rb interaction and displayed little to no detectable binding to wild-type IL-2Rb (Fig. 1H and figs. S7 and S8) but differed in their ability to activate IL-2Rb signaling in CD25-positive wild-type and orthoIL-2Rb T cells. Stimulation of orthoIL2Rb T cells ( fig. S5B ) with orthoIL-2 1G12 resulted in dose-dependent phosphorylation of STAT5 (pSTAT5), a hallmark of IL-2R signaling, with potency similar to that of wild-type IL-2, but also induced pSTAT5 on wild-type T cells, albeit with significantly reduced potency relative to IL-2 ( Fig. 1, G and I, and fig. S6 ). By comparison, orthoIL-2 3A10 was specific for orthoIL-2Rb T cells, but with a weaker potency relative to IL-2 ( Fig. 1, G and I, and fig. S6 ). We speculated that orthoIL-2 1G12 activity on wild-type T cells is a consequence of weak residual binding to wildtype IL-2Rb ( fig. S7 ). Low-affinity interactions with IL-2Rb alone are enhanced in the presence of CD25 (8) . Indeed, orthoIL-2 1G12 exhibited binding to wild-type IL-2Rb when first captured by CD25, with limited binding in the absence of CD25 (figs. S1 and S8). OrthoIL-2 3A10 did not bind appreciably to IL-2Rb even in the presence of CD25, in agreement with its negligible biological activity on CD25-positive T cells. Interaction of orthoIL-2 1G12 and 3A10 with orthoIL-2Rb was significantly enhanced in the presence of CD25, with apparent binding affinities of the ternary CD25/orthoIL-2Rb/orthoIL-2 complex that correlate with their respective potency on orthoIL2Rb T cells ( fig. S1 ).
In clinical ACT regimens, patient-derived T cells for ACT are expanded in IL-2 before re-infusion in order to obtain sufficient numbers of therapeutic cells with the desired genotype/phenotype (2). We explored the in vitro activity of orthoIL-2 on activated primary mouse CD8 + T cells engineered to express the orthoIL-2Rb and a yellow fluorescent protein (YFP) to distinguish modified (YFP + ) and unmodified (YFP -) cells ( Fig. 2A) . The transcription factor STAT5 is phosphorylated upon IL-2 engagement with the IL-2R and translocates to the nucleus, where it promotes the proliferation and cell cycle progression of T cells (11) . Wildtype IL-2 induced the phosphorylation of STAT5 (pSTAT5) in both wild-type and orthoIL-2Rb CD8 + T cells with similar potency and signaling amplitude, indicating functional signal transduction through the wild-type receptor but not orthoIL-2Rb (Fig. 2B ). By comparison, orthoIL-2 1G12 potently activated STAT5 on orthoIL-2Rb-transduced T cells, with a potency increase by a factor of~5 relative to wild-type T cells. OrthoIL-2 3A10 induced somewhat weaker, albeit selective pSTAT5 on orthoIL-2Rb-expressing but not wildtype T cells (Fig. 2 , B, D, and E). These results were consistent with the biased binding of the orthoIL2s to the orthoIL-2Rb, which translated into the selective or specific expansion of orthoIL-2Rb T cells cultured ex vivo in orthoIL-2 1G12 or 3A10, respectively (Fig. 2, C and D) . The orthoIL-2Rb-transduced T cells cultured in saturating concentrations of orthoIL-2 3A10 became enriched to near homogeneity after 3 to 5 days (Fig. 2F ).
IL-2 is indispensable for the development and function of regulatory T cells (T regs ) (12) , which are sensitive to IL-2 as a result of constitutive expression of CD25 and require IL-2Rb-dependent activation of STAT5 signaling for survival and function (13) . Both orthoIL-2 1G12 and 3A10 retained specificity for T regs modified to express the orthoIL-2Rb, with potency similar to that on CD8 + T cells (Fig. 2G and fig. S9 , A and B). In addition to cells that naturally respond to IL-2, activation of orthoIL-2Rb signaling pathways with orthoIL-2 could, in principle, be achieved in any cell type that also expresses the IL-2Rg. Activated mouse B cells expressed the IL-2Rg but lacked appreciable levels of IL-2Rb (14, 15) and were relatively insensitive to IL-2-dependent STAT5 activation Sockolosky ( Fig. 2H and fig. S9 , E and F). Transduction of the orthoIL-Rb into activated B cells rendered them responsive to orthoIL-2 ( Fig. 2H and fig. S9 , E and F), but with reduced potency and increased specificity relative to T cells. Specificity was due to the lack of appreciable wild-type IL-2Rb on B cells ( fig. S9E ). In a host with an intact immune system, adoptively transferred T cells must compete with host cells for survival signals such as IL-2 (16). However, unlike wild-type IL-2, there should be minimal competition from endogenous cells for orthoIL-2 consumption. Thus, we determined the in vivo activity of orthoIL-2 and orthoIL-2Rb T cells in mice with intact immune systems. A mixture of wild-type and orthoIL-2Rb CD8 + T cells was adoptively transferred into wild-type mice, and the impact of IL-2 and orthoIL-2 administration on transplanted T cells and the host immune system was quantified (Fig. 3A) . OrthoIL-2 1G12 significantly expanded CD8 + T cells transduced with the orthoIL-2Rb at doses equivalent to or lower than wild-type IL-2, which acted through the endogenous IL-2Rb expressed in both wildtype and orthoIL-2Rb T cells (Fig. 3B and fig. S10 ).
The selectivity of orthoIL-2 1G12 for orthoIL-2Rb T cells was dose-dependent, with increased activity on wild-type cells at increased dose amounts and/or frequency of treatment (Fig. 3, B and C, and figs. S10 to S12). These results were consistent with the in vitro selectivity of orthoIL-2 1G12, although it remained possible that orthoIL-2 1G12 signaling through the orthoIL-2Rb could trigger endogenous IL-2 production by the orthoIL-2Rb T cells, leading to indirect signaling through the wild-type IL-2R in cis or trans.
At high doses and twice-daily administration, orthoIL-2 3A10 resulted in the substantial expansion of orthoIL-2Rb T cells with high specificity and no wild-type T cell expansion (Fig. 3, B and C, and figs. S11 and S12). This finding suggests that the effects of high-dose orthoIL-2 1G12 treatment were due not to induction of endogenous IL-2 by orthoIL-2Rb CD8 + T cells, but rather to lowlevel cross-reactivity with the wild-type IL-2Rb by this molecule. The orthoIL-2 variants also promoted the in vivo expansion of orthoIL-2Rb CD4 + effector T cell (T eff ) (Fig. 3I and fig. S12 ) and orthoIL-2Rb CD4 + T reg ( fig. S9, C and D) cell subsets with specificity similar to that in CD8 + T cells.
The two different orthoIL-2 variants exhibited specificities in vivo that mirrored their relative specificities in vitro. Despite its ability to activate wild-type IL-2Rb signaling, albeit with about one order of magnitude less potency than orthoIL-2Rb signaling, orthoIL-2 1G12 administration was relatively specific for orthoIL-2Rb T cells in vivo (Fig. 3 , B to H, and figs. S10 to S12). In mice treated twice daily with orthoIL-2 1G12 only, CD4 + T regs were elevated to a substantially lower degree than observed in IL-2-treated mice (Fig. 3F) . However, the orthoIL-2 3A10 variant, consistent with the lack of wild-type IL-2Rb signaling, had no detectable activity on host cell subset numbers ( fig. S11) or expression of CD25, PD-1, and TIM-3, which are up-regulated by early or late IL-2R signaling ( fig. S13 ).
To improve in vivo half-life and enable more convenient dosing, we fused IL-2 and orthoIL-2 to mouse serum albumin (17) (MSA), which has been shown to extend the half-life of mouse IL-2 from 5 hours to 50 hours (18) . Fusion to MSA had little to no impact on IL-2-or orthoIL-2-dependent T cell proliferation in vitro (fig. S14) orthoIL-2 1G12 to MSA substantially increased its activity on cells that express the wild-type IL-2R relative to native orthoIL-2 1G12, leading to increased off-target effects and toxicity ( fig.  S15) . However, the MSA-orthoIL-2 3A10 fusion protein retained exquisite specificity for orthoIL2Rb T cells ( fig. S16) .
One of the major limitations of IL-2 in the clinic is that IL-2 toxicity limits the use of highdose IL-2 therapy for metastatic cancer and as an adjuvant to adoptive T cell therapy (12) . IL-2 administered as a MSA fusion resulted in a number of dose-dependent and dose-accumulating toxicities that led to weight loss, restricted mobility, hypothermia, ruffled fur, hunched posture, splenomegaly, lymphomegaly, and death (Fig. 3 , J to L, and figs. S15 to S18). In contrast, MSAorthoIL-2 3A10 was nontoxic at all doses evaluated. MSA-orthoIL-2 3A10 activity was negligible on all IL-2-responsive host cell subsets evaluated.
In addition to its role as a proliferative cytokine, IL-2 is a potent effector cytokine capable of activating cytotoxic T cell functions and T cell inflammatory pathways (19) . We determined the capacity of adoptively transferred orthoIL-2Rb CD8 + T cells to produce interferon-g (IFN-g) and cell surface levels of the immune inhibitory receptors PD-1 and TIM-3 after expansion in vivo with orthoIL-2. TIM-3 expression correlates with a highly dysfunctional CD8 + T cell state, whereas PD-1 expression is associated with both T cell activation and exhaustion (20) . OrthoIL-2Rb T cells expanded in orthoIL-2 produced significantly more Sockolosky IFN-g than IL-2-expanded cells (Fig. 4A) . PD-1 levels were similar on orthoIL-2Rb T cells from both IL-2-and orthoIL-2-treated mice (Fig. 4B) . Interestingly, TIM-3 levels were significantly lower on orthoIL2Rb T cells from mice treated with orthoIL-2 relative to those treated with IL-2 (Fig. 4B) . The differential activity of orthoIL-2 on both T cell expansion and function may be due to increased bioavailability of orthoIL-2 for orthoIL-2Rb T cells as the result of a reduced antigen sink or alternative host factors influenced by IL-2 but not orthoIL-2, which in turn may influence the function of transplanted T cells. For instance, IL-2 but not orthoIL-2 treatment increased host CD4 + and CD8 + T cell IFN-g production upon ex vivo restimulation (Fig. 3, M to O) and increased the serum concentration of numerous inflammatory cytokines, including IFN-g, IL-4, IL-5, IL-6, and IL-13 ( Fig. 3, P and Q, and fig. S17 ). The ability to decouple direct IL-2 activity on transplanted T cells from indirect host bystander effects using orthoIL-2/ IL-2R pairs may have important therapeutic implications.
To investigate prospective clinical applications of orthogonal IL-2/IL-2R pairs, we determined the efficacy of tumor-specific orthoIL-2Rb T cells in the B16-F10 mouse model of melanoma. Transgenic pmel-1 T cell receptor (TCR) cells (pmel-1 T cells) express a high-affinity TCR that recognizes the B16-F10 specific ortholog of human gp100 (19) , a self antigen overexpressed in human melanoma (Fig. 4, C and D) . Adoptive transfer of pmel-1 T cells in combination with lymphocyte depletion and IL-2 administration can model ACT approaches to treat human cancer. Adoptive transfer of pmel-1 T cells accompanied by five daily injections of IL-2 significantly delayed tumor growth in mice and increased survival relative to mice treated only with T cells and saline (Fig. 4, E to G) . Transfer of orthoIL-2Rb pmel-1 T cells followed by treatment with native orthoIL-2 1G12 at a dose that had minimal activity on wild-type IL-2R cells ( fig. S10 ) produced a significant tumor growth delay and survival advantage that mirrored the IL-2 treatment group (Fig. 4, E and F) . Similar antitumor responses were observed in mice treated with orthoIL-2Rb pmel-1 T cells and MSA-orthoIL-2 3A10 (Fig. 4, G and H) . There was no therapeutic benefit of orthoIL-2 in mice that received wildtype pmel-1 T cells, indicating that orthoIL-2 activity is dependent on expression of the orthoIL2Rb in pmel-1 T cells.
Our results constitute an approach to redirect the specificity of IL-2 toward engineered T cells using orthogonal IL-2 cytokine-receptor pairs, which enables the selective expansion of desired T cell subsets in settings of adoptive cell therapy, but with limited off-target activity and negligible toxicity. Engineering orthogonal molecular recognition at a protein-small molecule or protein-protein interface has resulted in synthetic enzymes, kinases, transcription factors, and receptors with controllable biological functions, but here we apply this concept to protein interactions with cell surface receptors to control signaling specificity and downstream cellular functions (21) (22) (23) (24) (25) (26) (27) (28) . Orthogonal IL-2/IL-2R pairs may be useful not only as a research tool but in the clinic to specifically enrich transduced T cells that express a target gene of interest, such as a CAR or engineered TCR, when coupled with expression of the orthoIL-2Rb. Our approach, and variations of this orthogonalization strategy, may be applicable to other cytokines, growth factors, hormones, and ligand-receptor interactions to decipher and manipulate otherwise complex biological systems. 
